Gerresheimer Glass Inc., USA, Gerresheimer Glas GmbH, Gerresheimer Group GmbH, and Gerresheimer AG entered into definitive agreements with an affiliate of funds advised by Apax Partners LLP (“Apax Funds”) regarding the sale of Centor US Holding Inc., USA, as well as Gerresheimer’s global Primary Packaging Plastics (PPP) business. The purchase price for the two business units combined is based on an enterprise value of approximately EUR 1.5 billion. The parties have agreed not to disclose further terms of the agreements. The transactions are subject to customary closing conditions and approvals and will be closed independently of one another.The sale of Centor is expected to close by the end of financial year 2026, while the sale of the global Primary Packaging Plastics business is expected to close in the first half of financial year 2027. Gerresheimer will use the expected cash inflows to significantly optimize its capital and financing structure by considerably decreasing its leverage.
“This transaction allows us to regain our strategic flexibility,” explains Uwe Röhrhoff, CEO of Gerresheimer AG. “At the same time, as a leading global partner to the pharmaceutical and biotech industries, we are focusing our business even more strongly on high-value drug delivery and medical devices, and primary packaging for injectable drugs.”
“Centor and Primary Packaging Plastics are market leaders in prescription vials and primary pharmaceutical packaging, built on a decades long reputation for quality and reliability. We have significant experience in carveouts and, together with our Operational Excellence Practice, we will work alongside management to establish a strong, standalone company positioned for long term growth,” says Anders Meyerhoff, Partner at Apax.
